Verastem (VSTM) Competitors $3.79 0.00 (0.00%) (As of 11:35 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VSTM vs. EPZM, MEIP, IRWD, EBS, RIGL, SGMO, CDXS, XOMA, VNDA, and LXRXShould you be buying Verastem stock or one of its competitors? The main competitors of Verastem include Epizyme (EPZM), MEI Pharma (MEIP), Ironwood Pharmaceuticals (IRWD), Emergent BioSolutions (EBS), Rigel Pharmaceuticals (RIGL), Sangamo Therapeutics (SGMO), Codexis (CDXS), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "medical" sector. Verastem vs. Epizyme MEI Pharma Ironwood Pharmaceuticals Emergent BioSolutions Rigel Pharmaceuticals Sangamo Therapeutics Codexis XOMA Vanda Pharmaceuticals Lexicon Pharmaceuticals Verastem (NASDAQ:VSTM) and Epizyme (NASDAQ:EPZM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Do insiders and institutionals hold more shares of VSTM or EPZM? 88.4% of Verastem shares are held by institutional investors. Comparatively, 76.5% of Epizyme shares are held by institutional investors. 2.2% of Verastem shares are held by company insiders. Comparatively, 23.4% of Epizyme shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in VSTM or EPZM? Verastem received 130 more outperform votes than Epizyme when rated by MarketBeat users. Likewise, 65.06% of users gave Verastem an outperform vote while only 60.53% of users gave Epizyme an outperform vote. CompanyUnderperformOutperformVerastemOutperform Votes60765.06% Underperform Votes32634.94% EpizymeOutperform Votes47760.53% Underperform Votes31139.47% Is VSTM or EPZM more profitable? Verastem has a net margin of 0.00% compared to Epizyme's net margin of -391.90%. Verastem's return on equity of -332.73% beat Epizyme's return on equity.Company Net Margins Return on Equity Return on Assets VerastemN/A -332.73% -73.97% Epizyme -391.90%-2,459.33%-69.74% Which has more volatility & risk, VSTM or EPZM? Verastem has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Comparatively, Epizyme has a beta of -0.41, indicating that its share price is 141% less volatile than the S&P 500. Does the media refer more to VSTM or EPZM? In the previous week, Verastem had 3 more articles in the media than Epizyme. MarketBeat recorded 3 mentions for Verastem and 0 mentions for Epizyme. Verastem's average media sentiment score of 0.64 beat Epizyme's score of 0.22 indicating that Verastem is being referred to more favorably in the media. Company Overall Sentiment Verastem Positive Epizyme Neutral Do analysts prefer VSTM or EPZM? Verastem presently has a consensus price target of $14.57, indicating a potential upside of 284.47%. Given Verastem's stronger consensus rating and higher possible upside, equities research analysts clearly believe Verastem is more favorable than Epizyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verastem 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Epizyme 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings & valuation, VSTM or EPZM? Verastem has higher earnings, but lower revenue than Epizyme. Verastem is trading at a lower price-to-earnings ratio than Epizyme, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerastem$2.60M64.88-$87.37M-$3.19-1.19Epizyme$37.43M6.61-$251.12M-$1.72-0.85 SummaryVerastem beats Epizyme on 13 of the 18 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VSTM vs. The Competition Export to ExcelMetricVerastemPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$168.69M$6.45B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E Ratio-1.1910.78126.3117.81Price / Sales64.88243.711,178.7474.57Price / CashN/A22.1633.8632.53Price / Book15.165.474.684.68Net Income-$87.37M$153.61M$119.54M$226.08M7 Day Performance-8.23%-2.00%-1.83%-1.04%1 Month Performance6.16%-7.46%-3.60%1.04%1 Year Performance-39.65%31.82%31.91%26.28% Verastem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VSTMVerastem2.7428 of 5 stars$3.79flat$12.50+229.8%-41.2%$168.69M$2.60M-1.1950Analyst DowngradeAnalyst RevisionNews CoverageEPZMEpizymeN/A$1.47flatN/A+0.0%$247.44M$37.43M-0.85250MEIPMEI Pharma4.1926 of 5 stars$2.77-1.1%$7.00+152.7%-50.5%$18.45M$65.30M-0.40100IRWDIronwood Pharmaceuticals4.2607 of 5 stars$3.46-1.7%$10.40+200.6%-63.0%$553.70M$442.73M-117.33220EBSEmergent BioSolutions4.5003 of 5 stars$9.25+4.2%$14.00+51.4%+322.9%$501.17M$1.05B-2.171,600Analyst DowngradeRIGLRigel Pharmaceuticals3.8438 of 5 stars$24.19-0.5%$31.30+29.4%+159.7%$425.99M$116.88M173.66147SGMOSangamo Therapeutics2.1854 of 5 stars$1.94-0.5%$7.00+260.8%+369.9%$404.78M$176.23M0.00480Analyst RevisionCDXSCodexis4.2117 of 5 stars$4.51+4.2%$8.33+84.8%+117.6%$367.02M$70.14M0.00250XOMAXOMA4.4424 of 5 stars$29.99-0.1%$78.50+161.8%+96.6%$353.28M$4.76M0.0010Positive NewsVNDAVanda Pharmaceuticals4.4351 of 5 stars$4.87-0.6%$15.50+218.3%+36.9%$283.97M$192.64M-17.50203LXRXLexicon Pharmaceuticals1.9831 of 5 stars$0.78-3.9%$6.00+673.1%-31.6%$191.11M$1.20M0.00285Analyst Revision Related Companies and Tools Related Companies Epizyme Alternatives MEI Pharma Alternatives Ironwood Pharmaceuticals Alternatives Emergent BioSolutions Alternatives Rigel Pharmaceuticals Alternatives Sangamo Therapeutics Alternatives Codexis Alternatives XOMA Alternatives Vanda Pharmaceuticals Alternatives Lexicon Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VSTM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VSTM Stock Alerts